Which form of systemic sclerosis (limited‑cutaneous vs diffuse‑cutaneous) is more likely to cause pulmonary hypertension and which is more likely to cause interstitial lung disease?

Limited Cutaneous SSc → Pulmonary Hypertension; Diffuse Cutaneous SSc → Interstitial Lung Disease

Limited cutaneous systemic sclerosis (lcSSc) is more strongly associated with pulmonary arterial hypertension (PAH), while diffuse cutaneous systemic sclerosis (dcSSc) is more strongly associated with interstitial lung disease (ILD). 1

Clinical Pattern Recognition

Diffuse Cutaneous SSc (dcSSc) and ILD

• ILD is clinically meaningful in 20% of dcSSc patients compared to only 12% of lcSSc patients 2
• ILD typically develops within the first 5 years of disease, often within 2 years of symptom onset 3
• At baseline assessment, 56% of dcSSc patients have ILD versus 35% of lcSSc patients 3
• Restrictive lung disease patterns on pulmonary function tests are significantly more frequent in dcSSc 4
• Strongly associated with anti-topoisomerase 1 (anti-Scl-70) antibodies, independent of disease subset 2
• Male sex increases ILD frequency, partly due to higher dcSSc prevalence in men 2

Limited Cutaneous SSc (lcSSc) and Pulmonary Hypertension

• PAH shows a trend toward higher prevalence in lcSSc 4
• lcSSc patients typically have a longer disease course before developing PAH 5
• Often presents later in disease compared to the early ILD seen in dcSSc 1
• Associated with anti-centromere antibodies (classic lcSSc marker) 2

Important Clinical Nuances

Both Can Occur in Either Subset

While the associations are clear, both complications can occur in either disease subset 4. The distinction is about relative frequency and timing, not absolute exclusivity. A minority of patients (particularly those with Th/To or U3RNP antibodies) can develop both PAH and ILD concomitantly 1.

No Direct Correlation with Skin Score

Extent of cutaneous involvement does not directly correlate with pulmonary disease severity 4. A patient with minimal skin thickening can still develop severe pulmonary complications, emphasizing the need for systematic screening regardless of skin involvement.

Screening Implications

All SSc patients require screening for both ILD and PAH, but the intensity and timing should be risk-stratified:

• dcSSc patients: Prioritize early and frequent ILD screening with pulmonary function tests and high-resolution CT, particularly in the first 3-5 years 2
• lcSSc patients: Maintain vigilance for PAH development with regular echocardiography, especially in those with longer disease duration 6
• Anti-Scl-70 positive patients: Aggressive ILD surveillance regardless of subset 2

Common Pitfall to Avoid

Do not assume that limited skin involvement means limited internal organ risk. lcSSc can cause life-threatening PAH despite minimal cutaneous disease 5. Similarly, the absence of extensive fibrosis on initial imaging does not exclude future ILD progression in dcSSc patients 2.